Finally, Some Good News for Dynavax Technologies
Hepatitis B is a potentially life-threatening liver condition that affects up to 250 million people globally, including 850,000 in the U.S. One of the most innovative biotechs with a treatment for this condition is Dynavax Technologies (NASDAQ: DVAX). The company is also partnered with two companies that have entered human trials for vaccine candidates against COVID-19, the disease caused by the novel coronavirus.
While the company has come a long way, many of its investors have waited years for Dynavax's promise to come to fruition. Today, let's look at why the company is a great long-term buy due to the strength of its recent catalysts.
Source Fool.com